Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study | Zendy

AI Assistant Blog Pricing

Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.